Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Oncostatin M" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oncostatin M, also known as OSM, is a protein that in humans is encoded by the OSM gene. OSM is a pleiotropic cytokine that belongs to the interleukin 6 group of cytokines. Of these cytokines it most closely resembles leukemia inhibitory factor (LIF) in both structure and function. However, it is as yet poorly defined and is proving important in liver development, haematopoeisis, inflammation and possibly CNS development. It is also associated with bone formation and destruction.
Immunoglobulins
InactiveUS20070286861A1Easy to neutralizeEffectively neutralising biological activity of cytokineAntipyreticAnalgesicsIntravenous gammaglobulinPharmaceutical drug
The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Owner:GLAXO GROUP LTD
Serum-free media and their uses for chondrocyte expansion
InactiveUS20070292949A1Enhance cell attachmentIncreased proliferationCulture processSkeletal disorderInterleukin 6Lipid formation
The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.
Owner:GENZYME CORP
Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof
Owner:NATIONAL YANG MING UNIVERSITY
Human Oncostatin M Antibodies and Methods of Use
ActiveUS20140099315A1Inhibit bindingAntibacterial agentsNervous disorderDiseaseIdiopathic pulmonary fibrosis
Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
Owner:JANSSEN BIOTECH INC
Human Oncostatin M Antibodies and Methods of Use
InactiveUS20120093833A1Preventing ligand ligation driven signalingPreventing downstream biological activityAntibacterial agentsAntipyreticDiseaseIdiopathic pulmonary fibrosis
Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
Owner:ALMAGRO JUAN CARLOS +3
Method for in vitro preparation of hepatocyte induced by umbilical cord blood hematopoietic stem cell
This invention discloses a method for producing liver cells by inducing haemopoietic stem cells in vitro, comprising: inoculating the haemopoietic stem cells or CD34+ cells into the culture media containing embryonic bovine serum, human stem cell factor, human interleukins 3(IL-3), interleukins 6(IL-6), human liver cell growth factor, human epidermal growth factor(EGF), human acdic fibroblast growth factor, human basic fibroblast growth factor(bFGF), human leukemia inhibitory factor(LIF) and oncostatin M(OSM), and inducing the producing of liver cells in vitro. By applying the method of this invention to induce liver cells from the haemopoietic stem cells, it can acquire a high proportion of liver cells in the culture with good effects.
Owner:EAST CHINA UNIV OF SCI & TECH
Simple and rapid derivation of functional hepatocytes from human bone marrow-derived mesenchymal stem cells
InactiveUS20050233449A1Culture processMammal material medical ingredientsMesenchymal stem cellIn vivo
This disclosure provides methods for preparing hepatocytes from mesenchymal stem cells by culturing in a first culture media comprising hepatocyte growth factor and a second culture media comprising oncostatin-M. The disclosure also provides the MSC-derived hepatocytes produced by these methods and both in vivo and in vitro uses for these MSC-derived hepatocytes.
Owner:LEE KUAN DER +1
Monkey homolog of human oncostatin m
Cytokine oncostatin M nucleic acids from Cynomolgus monkey are useful for expression of oncostatin M proteins that are functional homologs of human oncostatin M. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of oncostatin M, the generation and testing of oncostatin M modulators and related activities.
Owner:CENTOCOR ORTHO BIOTECH
Immunoglobulins
InactiveUS7858753B2Effectively neutralising biological activity of cytokineEasy to neutralizeNervous disorderAntipyreticMedicineMedical treatment
The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Owner:GLAXO GRP LTD
Serum-free media and their uses for chondrocyte expansion
InactiveUS20120213745A1Promote cell proliferationIncreased proliferationBiocideCulture processInterleukin 6Lipid formation
The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.
Owner:GENZYME CORP
Biomarker
ActiveUS20180022800A1Organic active ingredientsPeptide/protein ingredientsInflammatory Bowel DiseasesIntestinal inflammation
The invention relates to methods of treating chronic intestinal inflammation and / or inflammatory bowel disease by administering an antagonist of oncostatin-M (OSM) and / or OSM receptor-β (OSMR). The invention also relates to methods for diagnosing or prognosing chronic intestinal inflammation and / or inflammatory bowel disease in an individual and for predicting whether or not an individual will respond to an anti-TNFα therapy. The methods comprise measuring OSM and / or OSMR in the individual.
Owner:OXFORD UNIV INNOVATION LTD
Oncostatin m as promoter of immunostimulatory activity of human epithelial cells
InactiveUS20110195047A1Improved immunostimulatory activityHigh activityAntibacterial agentsAntimycoticsAgonistInterferon type I
The invention relates to the use of oncostatin M (OSM), an OSM receptor (OSMR) agonist, or a combination of OSM or a OSMR agonist with an interferon type I; in the manufacture of a medicament for enhancing the immunostimulatory activity of epithelial cells in a human.
Owner:UNIV DE NAVARRA +1
Immunoglobulins
InactiveCN1997668AImmunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsMedicineMedical treatment
The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Owner:GLAXO GROUP LTD
Antigen binding proteins to oncostatin m (OSM)
The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
Owner:GLAXO GROUP LTD
System and method for liver cell culture and maturation
InactiveUS20110014260A1Facilitates maturationEasy maintenanceBiocideHepatocytesMorphogenMorphogenesis
The present invention relates to systems and methods for maturation, proliferation and maintenance of function in cells presenting hepatocyte characteristics and differentiated from stem cells. The cells of the present invention may be generated from stem cell grown in collagen sandwich configuration in the presence of a morphogen (e.g. S-NitrosoAcetylPenicillamine (SNAP) or Oncostatin-M (OSM)).
Owner:RUTGERS THE STATE UNIV
Artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and biological product of such artificial polypeptide
ActiveCN107056895AArtificial cell constructsDepsipeptidesAcidic Fibroblast Growth FactorBiologic Products
The invention discloses an artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and a biological product of such artificial polypeptide. The artificial polypeptide is a polypeptide containing an amino acid sequence shown in formula (IV): LGENQPDAK(Xa)PCFQEDPMA(Xb)GTDCTLMEIWN, (IV), wherein each of Xa and Xb is selected from M, Y, L, V, W or E. Professionals in the field know that a strong ability to induce the bone mesenchymal stem cells to differentiate into the hepatic cells is achieved in case of combination of acidic fibroblast growth factor, hepatocyte growth factor and oncostatin M, and after induced culture for 14 days, alpha fetal protein mRNA and albumin mRNA in the cells are in remarkably positive expression. It is proven that the artificial polypeptide with the same effect is capable of inducing the bone mesenchymal stem cells to differentiate into the hepatic cells, and accordingly the artificial polypeptide can be prepared into the biological product for inducing the bone mesenchymal stem cells to differentiate into the hepatic cells.
Owner:诺赛联合(北京)生物医学科技有限公司
Serum-free media and their uses for chondrocyte expansion
InactiveUS20130273010A1Promote cell proliferationIncreased proliferationBiocideCulture processLipid formationInterleukin 6
The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.
Owner:GENZYME CORP
Method for induction of differentiation of es cell
InactiveUS20120058491A1Effectively lead to differentiationHigh sensitivityArtificial cell constructsCell culture active agentsDexamethasoneHepatocyte
It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M.
Owner:NAT UNIV CORP KUMAMOTO UNIV
Oncostatin m as promoter of immunostimulatory activity of human epithelial cells
The invention refers to the use of oncostatin M (OSM), an OSM receptor (OSMR) agonist, or a combination of OSM or of an OSMR agonist with an interferon of type I (IFN type I), in the manufacture of a medicament to increase the immunostimulatory activity of epithelial cells in a human.
Owner:PROYECTO DE BIOMEDICINA CIMA
Method of inducing differentiation of human pluripotent stem cell into hepatic progenitor cell
InactiveUS20130260458A1Induced differentiationPromotes proliferation and differentiationGenetically modified cellsDigestive systemGrowth promotingMonolayer culture
The present invention relates to a differentiation inducing method comprising: introducing, into human induced pluripotent stem cells, a combination of genes of transcription factors which are possessed by fetal and adult hepatic cells, but are not possessed by human induced pluripotent stem cells; and adhering the human induced pluripotent stem cells to a substrate for monolayer culture in a medium containing a combination of growth-promoting agents for proliferation and differentiation, thereby enabling induction of the differentiation of the human induced pluripotent stem cells in large amounts in a short term, a hepatic progenitor cell produced by the method, and a cell composition for transplantation into the liver comprising the cell. The transcription factors include FOXA2, GATA4, HEX and C / EBPα, and the growth-promoting agents include oncostatin M, an epidermal growth factor, retinoic acid, dexamethasone, insulin, transferrin and a selenite ion.
Owner:CHIBA UNIVERSITY
Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
ActiveUS9550828B2Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsDiseaseCancer prevention
A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
Owner:BOISE STATE UNIVERSITY
Viral propagation system and uses thereof
InactiveUS20050153280A1SsRNA viruses positive-senseMicrobiological testing/measurementDexamethasoneHepatitis B virus
Trans-differentiation induced by dexamethasone with or without oncostatin M results in cells that are capable of propagating and replicating hepatitis virus. Such trans-differentiated cells are useful for screening drugs that may affect the propagation and replication of hepatitis virus such as hepatitis B virus or hepatitis C virus.
Owner:BOARD OF RGT UNIV OF TEXAS SYST THE
Method for induction of differentiation of ES cell
InactiveUS8309353B2Effectively lead to differentiationHigh sensitivityArtificial cell constructsCell culture active agentsDexamethasoneHepatocyte
It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M.
Owner:NAT UNIV CORP KUMAMOTO UNIV
Application of oncostatin M in preparation of products for promoting mesenchymal stem cells to be in vitro directionally differentiated into bone cells
InactiveCN106119190AIncrease contentEasy to get materialsCell dissociation methodsSkeletal/connective tissue cellsDiseaseDirected differentiation
The invention belongs to the technical field of cell biotechnology and bone tissue engineering, and particularly relates to application of oncostatin M in preparation of products for promoting mesenchymal stem cells to be in vitro directionally differentiated into bone cells. Experiments prove that oncostatin M has functions of increasing expression of formed bone differentiation markers ALP, Runx2, OPN and OCN in mRNA and protein level and promoting the mesenchymal stem cells to be differentiated directionally into the bone cells. Application studying of oncostatin M matched with the mesenchymal stem cells in preparation of drugs for treating bone injury provides a material basis for development and preparation of drugs for treating diseases like osteoporosis, fracture bone loss and bone trauma.
Owner:吉林省中科生物工程股份有限公司
Culture method for long-term maintenance and proliferation subculture of human hepatocytes
A method for culturing hepatocytes involves maintenance, proliferation, and passaging of the hepatocytes. The method includes culturing the hepatocytes in a culture medium, which includes a hepatocyte basic medium; CHIR99021, which is a GSK-3 beta inhibitor at a concentration of 0.5-10 μM, SB 431542 or A83-01, which are RGF beta inhibitors, at a concentration of 0.5-10 μM, N-acetyl-cysteine at a concentration of 0.25-25 mM; and Oncostatin M at a concentration of 1-100 ng / mL There is no exogenous gene introduced into the hepatocytes, and the genetic background of the hepatocytes is not changed.
Owner:HEPATOBILIARY SURGERY HOSPITAL SECOND MILITARY MEDICAL UNIV
Methods and compositions for the treatment of an inflammatory bowel disease
Disclosed herein are methods for the treatment of an individual having an inflammatory bowel disease (“IBD”). The disclosed methods may include the detection of Oncostatin M (OSM) in a biological sample obtained from an individual having an IBD. The detection of OSM may be used to characterize the individual as a tumor necrosis factor (TNF) inhibitor (TNFi) responder or a TNFi non-responder for selection of appropriate treatment.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
Application of oncostatin-M as biomarker for preparing sepsis diagnosis reagent
InactiveCN109884320APredict therapeuticPrediction and/or prognosisBiological testingBiomarker (petroleum)Oncostatin M
The invention provides an application of oncostatin-M as biomarker for preparing sepsis diagnosis reagent. The invention provides a condition that the oncostatin-M can be used as a diagnosis index ofthe sepsis; the oncostatin-M can be used as an index for assessing the severity degree of the sepsis, and the treatment and / or prognosis of the sepsis can be predicted according to the oncostatin-M expression level.
Owner:CHONGQING MEDICAL UNIVERSITY
Human nasal mucosa epithelial cell inflammation model induced by oncostatin M combined with lipopolysaccharide as well as preparation method and application
ActiveCN113046301ATrue, Comprehensive and Accurate ScreeningReal, comprehensive and accurate evaluation of anti-inflammatory effectMicrobiological testing/measurementEpidermal cells/skin cellsNasal Cavity EpitheliumPharmaceutical drug
The invention discloses a human nasal mucosa epithelial cell inflammation model induced by oncostatin M combined with lipopolysaccharide as well as a preparation method and application. The model is prepared by a method comprising the following steps: inoculating human nasal mucosa epithelial cells into a culture medium for culturing to obtain human nasal mucosa epithelial cells growing in an adherent manner; replacing the culture medium, adding oncostatin M to culture the human nasal mucosa epithelial cells growing in an adherent manner, and then adding lipopolysaccharide to culture to obtain the model. According to the invention, OSM and LPS are combined to serve as irritants to treat human nasal mucosa epithelial cells HNEpC for the first time, OSM serving as a cell factor can destroy a barrier function of the epithelial cells, so that LPS binds to an intracellular receptor of the LPS to initiate an inflammatory reaction, as an induction condition, to construct a more effective and stable in-vitro nasal cavity inflammation model; and the model can be used to more truly, comprehensively and accurately reflect screening of nasal cavity medicine raw materials and products and evaluation of anti-inflammatory effects.
Owner:BLOOMAGE BIOTECHNOLOGY CORP LTD
Artificial polypeptides and their biological products for inducing differentiation of bone marrow mesenchymal stem cells into hepatocytes
ActiveCN107056895BArtificial cell constructsSkeletal/connective tissue cellsAcidic Fibroblast Growth FactorAmino acid
The invention discloses an artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and a biological product of such artificial polypeptide. The artificial polypeptide is a polypeptide containing an amino acid sequence shown in formula (IV): LGENQPDAK(Xa)PCFQEDPMA(Xb)GTDCTLMEIWN, (IV), wherein each of Xa and Xb is selected from M, Y, L, V, W or E. Professionals in the field know that a strong ability to induce the bone mesenchymal stem cells to differentiate into the hepatic cells is achieved in case of combination of acidic fibroblast growth factor, hepatocyte growth factor and oncostatin M, and after induced culture for 14 days, alpha fetal protein mRNA and albumin mRNA in the cells are in remarkably positive expression. It is proven that the artificial polypeptide with the same effect is capable of inducing the bone mesenchymal stem cells to differentiate into the hepatic cells, and accordingly the artificial polypeptide can be prepared into the biological product for inducing the bone mesenchymal stem cells to differentiate into the hepatic cells.
Owner:诺赛联合(北京)生物医学科技有限公司
Method for producing mesothelial cells and a cell sheet for preventing adhesion
An object of the present invention is to provide a method for differentiating mesodermal cells into mesothelium cells. The present invention provides a method for producing mesothelial cells, including a first culturing step of culturing mesodermal cells in a medium containing basic fibroblast growth factor (bFGF) and oncostatin M.
Owner:THE UNIV OF TOKYO
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com